Detailed Explanation
Breakthrough Therapy Designation represents the most intensive FDA expedited program, created by the FDA Safety and Innovation Act of 2012 to accelerate development of drugs that show early evidence of transformative clinical benefit. While Fast Track focuses on drugs that may address unmet need, Breakthrough Therapy requires preliminary clinical evidence of substantial improvement over existing treatments, reflecting a higher bar that identifies drugs with exceptional therapeutic potential deserving the most intensive agency engagement.
The evidentiary standard for Breakthrough Therapy Designation requires preliminary clinical evidence, typically from early-phase trials, demonstrating substantial improvement over available therapy on clinically significant endpoints. The comparison is made to existing treatments, not to placebo, meaning that the drug must show potential to meaningfully advance the therapeutic landscape. The substantial improvement may be based on efficacy, safety, or other clinically meaningful advantages. This evidence requirement distinguishes Breakthrough Therapy from Fast Track, which can be granted based on potential rather than demonstrated benefit.